CytoMed Therapeutics (NASDAQ:GDTC) Trading Up 3%

CytoMed Therapeutics Limited (NASDAQ:GDTC) shares were up 3% during trading on Thursday . The stock traded as high as $1.74 and last traded at $1.73. Approximately 19,362 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 43,155 shares. The stock had previously closed at $1.68.

Analyst Upgrades and Downgrades

Separately, Benchmark reissued a “speculative buy” rating and issued a $5.00 target price on shares of CytoMed Therapeutics in a research note on Tuesday, June 11th.

CytoMed Therapeutics Stock Down 3.9 %

The stock’s 50 day simple moving average is $1.95 and its two-hundred day simple moving average is $2.14. The company has a current ratio of 14.09, a quick ratio of 14.09 and a debt-to-equity ratio of 0.04.

About CytoMed Therapeutics

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity.